secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001558370-25-000093
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma reports preliminary 2024 IMCIVREE sales of $130M, up 68% YoY; Phase 3 HO data on track for H1 2025
--------------------------------------------------------------------------------

- Preliminary Q4 2024 IMCIVREE net revenues of ~$42M, up 26% sequentially; full year ~$130M vs $77.4M in 2023.
- U.S. sales contributed ~74% of Q4 and ~73% of full year 2024 revenues.
- Topline data from Phase 3 acquired hypothalamic obesity trial expected in first half of 2025; completed Japanese cohort.
- Phase 3 EMANATE enrollment completed across four substudies; topline data anticipated first half of 2026.
- New Phase 2 trial of setmelanotide in Prader-Willi syndrome to initiate Q1 2025 (up to 20 patients, 26 weeks).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/0001558370-25-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000155837025000093/rytm-20250110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer